Drug intelligence / Profile preview

ADX-850

Development stage: Phase 1
Lead developer: ADARx Pharmaceuticals
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

ADX-850 is a small interfering RNA (siRNA) duplex oligonucleotide therapeutic candidate developed by ADARx Pharmaceuticals for the treatment of hypertension. It is designed to selectively and durably inhibit angiotensinogen (AGT) production in the liver, while sparing renoprotective AGT production in the kidney. By targeting AGT, which is a principal component of the renin-angiotensin-aldosterone system (RAAS), ADX-850 aims to provide effective and convenient blood pressure control. The drug utilizes RNA interference as its mechanism of action and is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension[1][2][3][4][5][6].

Other names: siRNA duplex oligonucleotide - ADARx

Targets

AGT (O6-methylguanine-DNA methyltransferase)

Beyond the preview

Go deeper on ADX-850.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX-850.

Explore the full profile